Price
$20.59+52.41%Social Signal Score
Analyst Ratings
4 analystsRevenue
$16.19M+318.91%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Joseph Ball
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 74
- Beta
- -1.77
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 8.78
Financials
Revenue
$16.19M+318.9%Net Income
$-7.05MEBITDA
$-5.93MFree Cash Flow
$-6.98MEPS (diluted)
$-0.34Shares Outstanding (diluted)
20.84M+4.6%Operating Expenses
$20.30MCash & Debt
$92.33MRevenue by Segment (annual)
$47.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $47.32M | $-40.36M | $-1.96 |
| 2024 | $31.62M | $-15.62M | $-0.77 |
| 2023 | $19.27M | $-12.65M | $-0.63 |
Valuation
SIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
165+450.00%Social Signal Score
Mentions (12)
- Newsmarketbeat.com·9d ago·Neutral
Shoulder Innovations Doubles Customer Growth, Sets Sights on Surgical Robotics Shoulder Innovations NYSE: SI is targeting high-volume shoulder surgeons with its implant system and planning technology while developing a portable surgical robot and considering expansion into soft-tissue procedures, CEO Rob Ball said during a discussion with UBS MedTech's Patrick Wood.
View source ↗ - Newszacks.com·9d ago·Positive
Does Shoulder Innovations, Inc. (SI) Have the Potential to Rally 25.24% as Wall Street Analysts Expect? The consensus price target hints at a 25.2% upside potential for Shoulder Innovations, Inc. (SI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·12d ago·Positive
Here's Why Shoulder Innovations, Inc. (SI) is a Great Momentum Stock to Buy Does Shoulder Innovations, Inc. (SI) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
What Shoulder Innovations (SI) Said on Its Q3 Earnings Call Shoulder Innovations NYSE: SI raised its full-year revenue outlook after reporting 38% growth in the third quarter, as new surgeon additions and higher use of its implants by existing customers helped offset seasonal pressure on procedures.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Shoulder Innovations, Inc. (SI) Q3 2026 Earnings Call Transcript Shoulder Innovations, Inc. (SI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·26d ago·Neutral
…ticipate in Upcoming Investor Conferences GRAND RAPIDS, Mich., Oct. 27, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management will participate in the following upcoming investor conferences: UBS Global Healthcare Conference Format: Fireside chatDate: Tuesday, November 10Fireside chat time: 3:30…
View source ↗ - Newsprnewswire.com·38d ago·Neutral
Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026 GRAND RAPIDS, Mich., Oct. 15, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
…sful Completion of First Surgical Case GRAND RAPIDS, Mich., Oct. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has initiated a limited user release of the InSet® Go, the company's next-generation glenoid implant, for use in anatomic shoulder arthroplasty procedures.
View source ↗ - Newsprnewswire.com·74d ago·Negative
…ex Shoulder Reconstruction Procedures GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has entered into an exclusive collaboration with ALM Ortho, Inc. ("ALM Ortho"), a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the treatm…
View source ↗ - Newsprnewswire.com·75d ago·Negative
…tlement of Patent Litigation with Catalyst OrthoScience GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. ("Catalyst") to resolve all outstanding patent litigation between the two companies.
View source ↗ - Newsprnewswire.com·104d ago·Neutral
Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer GRAND RAPIDS, Mich., Aug. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026.
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Shoulder Innovations Q2 Earnings Call Highlights Shoulder Innovations NYSE: SI reported second-quarter net revenue of $17.2 million, up 56% from $11 million a year earlier, as the company added surgeons, expanded use among existing customers and advanced several product launches. The company raised its full-year 2026 revenue outlook to $67 million to $69 million, from a prior range of $65 million to $68 million.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $-0.47 per share
Typical surprise +6.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.34 vs $-0.49beat
- Thu, Aug 6$-0.46 vs $-0.46miss
- Wed, May 13$-0.41 vs $-0.44beat
- Tue, Mar 10$-0.38 vs $-0.42beat
- Tue, Nov 11$-0.48 vs $-0.37miss
- Tue, Sep 9$-0.64 vs $-0.01miss
Estimates and results for SI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SI officers and directors.
- Bought
- $5.9m
- Sold
- $5.5m
12 trades
17 trades
- Ball Robert Josephsold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Ahearn Matthew Frasersold
- Ahearn Matthew Frasersold
- Ahearn Matthew Frasersold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Sep 9, 2022 (53d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 3, 2022 (3d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (178d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 2, 2020 (12d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
